Advances in GLP-1 receptor agonists for the treatment of type 2 diabetes
BIO Web of Conferences, ISSN: 2117-4458, Vol: 61
2023
- 2Captures
- 1Mentions
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Captures2
- Readers2
- Mentions1
- News Mentions1
- 1
Most Recent News
Sichuan University Researcher Reports Recent Findings in Type 2 Diabetes (Advances in GLP-1 receptor agonists for the treatment of type 2 diabetes)
2023 AUG 04 (NewsRx) -- By a News Reporter-Staff News Editor at NewsRx Diabetes Daily -- Investigators discuss new findings in type 2 diabetes. According
Conference Paper Description
Glucagon-like peptide-1 (GLP-1), an incretin secreted by intestinal L cells, has become a critical target for the treatment of type 2 diabetes because of its physiological effects of augmenting insulin secretion, suppressing glucagon secretion, and decelerating gastric emptying. Human endogenous GLP-1 is found to be proteolytically degraded and inactivated by DPP-4, which considerably limits the therapeutic effects of GLP-1. In contrast, GLP-1RAs undergo significant improvement in drug stability. In this context, several successful strategies for the development of GLP-1RAs and the corresponding problems are fully elaborated. The assay gives a brief overview of the pharmacological effects, advantages and common adverse effects of GLP-1RAs, shedding light on the latest research progress of GLP-1RAs, including new dosage forms, new drug targets and new clinical applications.
Bibliographic Details
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know